Opioids are medications prescribed by
doctors and physicians to treat various levels of pain. These can include acute
pain and chronic non-cancer pain. They are also known as painkillers and used
to block pain signals from the brain. Market Research Future (MRFR) has
stressed the advantages of the intake of opioids as well as the efforts by
manufacturers to address various issues concerning the drugs.
Growth Drivers
The opioids
market is expected to reach USD 6,060.17 million at CAGR of 4.90% during
the forecast period 2022-2030. Pain management of various chronic diseases
remain the primary driver of the market. According to the National Institute of
Drug Abuse, nearly 200 million prescriptions were dispensed by U.S. pharmacies
in 2017. The large number of prescriptions is an indicator for the large scope
of the market.
Favorable reimbursement schemes for
covering the costs of opioids in palliative care can work in favor of the
market. Large number of patients diagnosed with various cancers can drive the
market demand for opioids till 2023. Rise in surgical procedures and road
accidents are other factors which can contribute to market demand due to the
need for pain relievers. All of these factors are predicted to push the market
to exhibit a CAGR of 7.12% during the forecast period.
Establishment of new guidelines to curb the
intake of opioids and reduce the addiction rates are expected to disrupt the
market in a positive manner. For instance, the sale of over-the-counter drugs
containing opioids is restricted, while stringent measures are undertaken regarding
prescriptions given by doctors. New policies by government-supported insurance
companies such as Medicare are limiting the dispensation rate of opioids to 7
days.
But misuse of viatris opioids and adverse
effects of the drugs which lead to addiction threaten the market growth.
Segments In-Detail:
MRFR has segmented the global opioids
market by product, application, and end-user.
Based on the product, the market is
segmented into immediate release/short-acting opioid and extended
release/long-acting opioid. Extended release comprises hydromorphone,
oxycodone, morphine, oxymorphone, and others. The extended release segment had
accounted for USD 12,750.91 million in 2017. This segment can expand in the
coming years due to rising prevalence of chronic diseases.
By application, it is segmented into
diarrhea suppression, deaddiction, cough suppression, pain relief, anesthesia,
and others. The pain relief segment is expected to be the dominant application
of the opioids market due to rise in pain management therapies. Moreover, new
guidelines for selling prescription drugs coupled with rise in palliative and
end-of-life care can boost segment growth. This in turn can drive the market
demand exponentially.
By end-user, the market caters to academic
research institutes, hospitals & clinics, and pharmacies.
Regional Analysis:
MRFR’s report takes a deep look into major
regions which include the Americas, Europe, Asia Pacific (APAC), and the Middle
East and Africa (MEA).
The Americas is predicted to be dominant in
the global market due to holding the largest market share due to awareness
among patients and the high intake of the drugs for pain alleviation. On the
other hand, Europe is expected to showcase prolific growth due to rise in
palliative care centers and strict regulations regarding opioid usage.
A Look at the Competition:
Prominent companies operating in the opioids
market players include Janssen Global Services, LLC, Egalet Corporation,
Teva Pharmaceutical Industries Ltd, Pfizer Inc., Sanofi SA, Purdue Pharma L.P,
Boehringer Ingelheim GmbH, Allergan Inc., Sun Pharmaceutical Industries Ltd.,
Mallinckrodt, Vertice Pharma LLC, and West-Ward Pharmaceuticals
Corporation.
New in Research
Opioid-induced constipation is on the rise
due to being one of the side-effects during intake of pain relievers. In 2019,
Novartis has agreed to partner with Shinogi & Co Ltd, for bringing to
market Rizmoic in selected areas of the Netherlands, the U.K., and Germany.
According to a study published by the
researchers at the University of Pennsylvania School of Medicine, patients in
the United States and Canada are more likely to procure opioids due to the
large number of chronic diseases. High prevalence of minimally invasive
surgeries and prescription of codeine in post-operative care can bode well for
the global opioids market in the coming years.
About US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
The Wall